Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

Health technology assessment (HTA) plays an important role in reimbursement decision-making in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. This variation may be due to differences in the weighing of evidence or differences in the processes or pro...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2020-01, Vol.23 (1), p.10-16
Main Authors: Vreman, Rick A., Mantel-Teeuwisse, Aukje K., Hövels, Anke M., Leufkens, Hubert G.M., Goettsch, Wim G.
Format: Article
Language:English
Subjects:
conditional marketing authorization
Cost analysis
cost-effectiveness assessment
Decision making
differences
evidence
Health technology assessment
Jurisdiction
Medical technology
Negotiation
practice
procedure
process
Public health
regulation
reimbursement
relative-effectiveness assessment
Technology assessment
Variation
Weighing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Health technology assessment (HTA) plays an important role in reimbursement decision-making in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. This variation may be due to differences in the weighing of evidence or differences in the processes or procedures, which are known as HTA practices. To provide insight into the effects of differences in practices on interpretation of intercountry differences in HTA recommendations for conditionally approved drugs. HTA recommendations for conditionally approved drugs (N = 27) up until June 2017 from England/Wales, France, Germany, the Netherlands, and Scotland were included. Recommendations and practice characteristics were extracted from these five jurisdictions and this data was validated. The effect of nonsubmissions, resubmissions, and reassessments; cost-effectiveness assessments; and price negotiations on changes in the percentage of negative recommendations and the interpretation of intercountry differences in HTA outcomes were analyzed using Fisher exact tests. The inclusion of cost-effectiveness assessments led to significant increases in the proportion of negative recommendations in England/Wales (from 4% to 50%, P
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2019.07.017